13F Holdings
中文EN

TSHA Taysha Gene Therapies, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1806310 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-13.1%
TTM net income YoY-56.1%
TTM EPS YoY-27.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,935.4%
Net margin-2,844.6%
FCF margin-2,582.6%
EBITDA margin-2,913.6%

Returns

ROE-54.2%
ROA-41.5%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets17.9%
Debt / equity0.13x
Current ratio18.56x
Interest coverage-5,193.77x

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue13.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$9.77M$8.33M$15.45M$2.50M—
R&D expense$86.40M$66.00M$56.78M$91.17M$131.94M
SG&A expense$33.87M$28.95M$30.05M$37.36M$41.32M
Operating income-$110.50M-$91.46M-$72.44M-$162.45M-$173.27M
Interest expense$63,000$102,000$5.00M$3.80M$1.43M
Income tax$0$0$0$0—
Net income-$109.00M-$89.30M-$111.57M-$166.01M-$174.52M
EBITDA-$109.35M-$90.21M-$71.07M-$161.28M-$172.78M
EPS (basic)-0.34-0.36-0.96-3.78-4.64
EPS (diluted)-0.34-0.36-0.96-3.78-4.64
Weighted avg. shares (diluted)319.71M250.13M116.12M43.95M37.65M
Balance sheet
Cash & equivalents$319.77M$139.04M$143.94M$87.88M$149.10M
Current assets$324.65M$142.13M$149.87M$96.42M$159.60M
PP&E, net$6.74M$7.49M$10.83M$14.96M$50.61M
Total assets$343.32M$160.36M$172.73M$126.28M$213.96M
Current liabilities$26.55M$26.23M$36.76M$62.79M$51.75M
Long-term debt$50.11M$43.94M$40.51M$37.97M$37.19M
Total debt$50.11M$43.94M$40.51M$37.97M$37.19M
Total liabilities$96.38M$88.84M$97.79M$125.33M$118.57M
Shareholders' equity$246.94M$71.53M$74.94M$949,000$95.38M
Net debt-$269.66M-$95.09M-$103.43M-$49.91M-$111.91M
Shares outstanding285.05M204.94M186.96M63.21M38.47M
Cash flow statement
Operating cash flow-$93.09M-$81.22M-$73.02M-$88.39M-$117.04M
Capital expenditure$738,000$374,000$3.87M$20.62M$15.30M
Free cash flow-$93.83M-$81.60M-$76.89M-$109.01M-$132.35M
Investing cash flow-$604,000-$363,000-$7.35M-$24.93M-$21.55M
Financing cash flow$274.59M$76.68M$136.39M$52.10M$39.08M
Depreciation & amortization$1.15M$1.25M$1.37M$1.17M$492,000
Stock-based compensation$13.30M$13.10M$7.91M$18.04M$18.18M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.